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Resveratrol (RSV), a natural polyphenol found in grapes, was found to be effective in the prevention 
and therapy of several diseases, however, it does have unfavourable physicochemical properties. In 
this context, an increasing number of studies have aimed at developing novel therapeutic systems for 
its delivery to overcome these disadvantages. This review focuses on the mechanisms of action and 
therapeutic applications. Finally, it also describes some tested formulations for RSV administration, 
controlled release and targeting, developed with the purpose of increasing RSV bioavailability.
Uniterms: Nutraceuticals. Natural polyphenols. Resveratrol/mechanisms of action. Resveratrol/
therapeutic applications. Resveratrol/delivery systems.
O resveratrol (RSV) é um polifenol natural encontrado nas uvas, que se mostrou eficaz na prevenção 
e terapia de várias doenças. No entanto, apresenta propriedades físico-químicas desfavoráveis. Neste 
contexto, um número cada vez maior de estudos visando ao desenvolvimento de novos sistemas 
terapêuticos para a sua liberação vem sendo desenvolvido no sentido de ultrapassar estas desvantagens. 
Esta revisão discorre sobre os mecanismos de ação e aplicações terapêuticas do RSV. Finalmente, são 
abordadas algumas formulações de liberação controlada e vetorizada, testadas para administração do 
RSV, desenvolvidas com a finalidade de aumentar a biodisponibilidade do RSV.
Unitermos: Nutracêuticos. Polifenóis naturais. Resveratrol/mecanismo de ação. Resveratrol/aplicações 
terapêuticas. Resveratrol/sistemas de liberação.
INTRODUCTION
The term nutraceutical (a combination of the terms 
‘nutrient’ and ‘pharmaceutical’) is commonly given to 
dietary supplements which provide a concentrated dosage 
of a bioactive compound present in food, supplying higher 
dosages than those obtained from normal nutritional 
values in foods, and available in normal pharmaceutical 
forms (pills, powders, capsules, vials, extracts etc.) 
(Espín, García-Conesa, Tomás-Barberán, 2007). These 
products, intended for health promotion through disease 
prevention and/or treatment, can be divided into several 
classes, among which pro- and prebiotics, sulphured and 
nitrogenized foods, antioxidant vitamins, polyunsaturated 
fatty acids, oligosaccharides and polyphenols are of 
particular interest (Moraes, Colla, 2006).
Plants, including food plants (vegetables and 
fruits), synthesize a wide array of chemical compounds, 
important in serving a variety of ecological functions that 
not only enhance the plant’s survivability, but may also be 
responsible for a multitude of beneficial effects reported 
for health-related bioactivities (Joseph et al., 2008; 
Svobodová, Psotová, Walterová, 2003). In these terms, 
the resultant chemical compounds of the plant’s primary 
and secondary cellular metabolism may be applied in the 
vast health-related arsenal, also bearing in mind the global 
resurgence in both medicine and natural cosmetics, in great 
part due to society’s demands for options in ecological, 
safe and economic techniques.
More accurately, polyphenols, as ‘secondary’ 
chemical compounds, represent molecules exhibiting 
a common phenol structure, with a benzenic nucleus 
aromatic ring linked to at least one hydroxyl (OH-) group, 
free or belonging to esters, ethers or heterosides. These 
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compounds, not synthesized by humans, are present in 
the daily diet, such as fruits, vegetables, cereals and drinks 
(tea, coffee and wine), especially in the Mediterranean 
diet. They represent serious candidates for the prevention 
of many pathologic states, as for example photoaging and 
cancer; this is essentially associated to their antioxidant 
activity (Moraes, Colla, 2006; Proença da Cunha, 2005; 
Svobodová, Psotová, Walterová, 2003).
Experimental studies support their preventive 
role in several diseases, in which oxidative stress seems 
to represent the principal and important precipitating 
factor. Resveratrol (RSV), a polyphenol and stilbene 
derivative, represents a naturally occurring triphenolic 
phytoalexin (Figure 1), or plant antibiotic (Bishayee, 
2009; Harikumar, Aggarwal, 2008). It is synthesized by 
certain species and genera of higher plants via shikimic 
acid or acetic metabolic pathways (phenylalanine being 
the RSV’s precursor and stilbene synthase the enzyme that 
catalyses the reaction), triggered by exogenous plant stress 
conditions, such as microbial/fungal infection, injury, 
ultraviolet (UV) irradiation and exposure to heavy metal 
ions, serving as a first line of chemical defense (Das et al., 
2008; Hung et al., 2008; López-Nicolás, García-Carmona, 
2008; Lu et al., 2009; Lucas-Abellán et al., 2011; Murias 
et al., 2005; Santos, Veiga, Ribeiro, 2011; Smoliga, Baur, 
Hausenblas, 2011; Snyder, Gollner, Chiriac, 2011).
First isolated from the roots of white hellebore 
(Veratrum glandiflorum), the extract of which contains 
trans-RSV of a purity range of 10% to 99%, RSV is mainly 
found in daily foods, such as grapes (fresh grape skin 
contains about 50-100 µg of RSV), red wine (1.5-3 mg/L 
of RSV), cranberries, peanuts, and was recently discovered 
in chocolate, cocoa and tomato (Amri et al., 2012; Counet, 
Callemien, Collin, 2006; Harikumar, Aggarwal, 2008; 
Huang, Zhu, 2011; Ragab et al., 2006; Syed, Mukhtar, 
2011). Several epidemiologic studies have reported RSV, 
present in red wine, as responsible, at least in part, for 
the ‘French paradox’, the apparent ability of moderate 
consumption of red wine to reduce cardiovascular disease, 
reflected by the low incidence of coronary heart disease 
mortality in France in relation to other countries, despite its 
culture of a fat-rich diet (Bishayee, 2009; Lucas-Abellán 
et al., 2007; Smoliga, Baur, Hausenblash, 2011).
The following applications reported for this stilbene 
are, in great part, underestimated, as this molecule is 
subject to extensive pre-systemic metabolism through 
first-pass glucuronidation and sulphate conjugation (phase 
II conjugation reactions), both in the small intestine and 
the liver (Figure 2). This is often assigned as the main 
cause of the trace amounts of it found in human plasma 
(less than 5 ng/mL), and consequently responsible for its 
restricted oral bioavailability (Amri et al., 2012; Das et 
al., 2008; Huang, Zhu, 2011; Hung et al., 2008; Muzzio 
et al., 2012; Rotches-Ribalta et al., 2012; Santos, Veiga, 
Ribeiro, 2011).
THERAPEUTICAL APPLICATIONS OF RESVE-
RATROL
RSV has received considerable attention, as several 
in vitro and in vivo studies report its variable biological 
activities, and its potential as a disease-preventing 
agent, since this compound shows promising properties 
in the prevention and treatment of a wide variety of 
chronic ailments, including cardiovascular, pulmonary 
and neurodegenerative diseases, obesity, diabetes, skin 
disorders, arthritis, cancer and even the aging process 
(Harikumar, Aggarwal, 2008; Murias et al., 2005; Muzzio 
et al., 2012; Santos, Veiga, Ribeiro, 2011; Smoliga, Baur, 
Hausenblash, 2011). These studies have demonstrated 
that RSV has antioxidant properties at low oral doses (10 
µM), acting as a potent radical scavenger, as it modulates 
lipid metabolism, protects low density lipoproteins (LDL) 
FIGURE 1 - Resveratrol chemical structure.
FIGURE 2 - Resveratrol simplified metabolism (RSV – 
Resveratrol; GLU-RSV – Resveratrol glucuronide form; 
SUL-RSV – Resveratrol sulphated form) (adapted from 
(Halilbasic, Claudel, Trauner, 2013).
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against oxidative and free radical damage, and inhibits 
platelet activation and aggregation. It also demonstrates 
strong chemopreventive and cytostatic effects at higher 
concentrations (100 µM), blocking the carcinogenesis 
principle stages of initiation (changes at the genetic 
level), followed by promotion and progression, that finally 
culminate in malignancy (Amri et al., 2012; Bhat, Pezzuto, 
2002; Bishayee, 2009; Caddeo et al., 2008; Kundu, Surh, 
2008; Murias et al., 2005; Santos, Veiga, Ribeiro, 2011).
Other pharmacological activities of RSV include being 
anti-inflammatory, antimicrobial against dermatophytes and 
herpes simplex, analgesic, and anti-aging, the last only 
seen, at the moment, in lower organisms, such as yeast, 
mice and fish (Amri et al., 2012; Cottart et al., 2010; 
Harikumar, Aggarwal, 2008; Smoliga, Baur, Hausenblash, 
2011). Concerning these properties, RSV has been subject 
to several clinical trials, and much of the published data on 
RSV in humans is summarized in Table I.
Resveratrol mechanisms of action
In terms of the mechanisms of action, RSV may 
display dual proceedings (cell protection or cell apoptosis) 
depending on the cellular conditions, concentration used, 
cytosolic redox status and duration of contact (Caddeo 
et al., 2008; Huang, Zhu, 2011; Santos, Veiga, Ribeiro, 
2011). The chemical structure of RSV allows it to interact 
with several receptors, kinases and other enzymes, which 
may lead to the prevention of many disease conditions that 
are the consequence of cell damage or death, triggered 
by severe oxidative stress, including Alzheimer’s, 
Parkinson’s, cancers, heart disease, multiple sclerosis, and 
others (Huang, Zhu, 2011; Santos, Veiga, Ribeiro, 2011; 
Smoliga, Baur, Hausenblash, 2011).
Antioxidant activity
Similar to most polyphenols, RSV displays intrinsic 
antioxidant activity, acting as a potent radical scavenger, 
inhibiting hydrogen peroxide- or lipid hydroperoxide-
dependent lipid peroxidation of cellular membrane 
lipids, thus protecting the systemic erythrocytes. 
Additionally, RSV also supresses the activity of the 
lipopolysaccharide-inducible form of nitric oxide synthase 
by the vascular endothelium, demonstrated by a decrease 
in nitric oxide production, also inhibiting the oxidation 
of the LDL through the in vivo chelation of copper, 
therefore suggesting a possible role in the prevention of 
atherosclerosis and coronary heart disease (Amri et al., 
2012; Bhat, Pezzuto, 2002; Harikumar, Aggarwal, 2008; 
Kundu, Surh, 2008; Smoliga, Baur, Hausenblash, 2011). 
It is worth noting that RSV’s antioxidant effects are most 
likely mediated through its ability to induce antioxidant 
enzymes, such as catalase, superoxide dismutase and 
glutathione peroxidase hemoxygenase (Hsieh, Wu, 2010).
TABLE I - Human clinical trials performed using RSV
Aim of Study Dose Volunteers Results 
Safety and dose-finding 0-5 g (oral) 10 Safe up to 5 g; highest blood levels 1.5 h after 
intake; rapid urinary excretion (Kim et al., 2006)
Safety, pharmacokinetics, 
dosing with quercetin/alcohol
2000 mg twice/daily 8 RSV was well tolerated, but 6/8 volunteers 
reported diarrhoea (Kim and Snyder, 2010)
Effects of food on RSV 
absorption
400 mg 24
The extent of absorption was not affected by food, 
but the rate of absorption was delayed with food 
(Ansari et al., 2011)
Pharmacokinetics of multiple 
doses 0–150 mg, 6x/day 40
Repeated  dos ing wel l  to lera ted;  h igher 
bioavailability after morning administration 
(Mehnert, Mäder, 2001)
Bioavailability from red wine
246 µg–1.92 mg 
(three different wines)
25
Trace amounts found in some subjects 30 minutes 
after ingestion (Atanacković, Gojković-Bukarica 
and Cvejić, 2012)
Glycemic control 250 mg 72
Improvement of glycemic control in type 2 
diabetes mellitus (Bhatt, Thomas, Nanjan, 2012)
Effect in healthy smokers 500 mg 50 Significant reduction in C-reactive protein and 
triglyceride concentrations (Bo et al., 2013)
Effect in non-alcoholic fatty 
liver disease 2150 mg 60
Significant improvement of insulin resistance, 
glucose and lipid metabolism (Chen et al., 2015)
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Anti-aging capacity
Another interesting application of RSV is related 
to its anti-aging capacity, as RSV is responsible for the 
enhancement on the genetic expression of the Silent 
Information Regulator2, a gene associated with longevity, 
whose homolog in mammals is known as SIRT1, being 
responsible for the codification of the sirtuin enzymes 
(NAD+-dependent histone deacetylases, involved in gene 
silencing processes, blockade of apoptosis and promotion 
of cell survival), mimicking the known lifespan-extending 
effects of caloric restriction or partial food deprivation on 
lipid metabolism, gluconeogenesis and liver glycolysis 
monitoring, as caloric restriction was found to reduce 
inflammation, atherosclerosis, effects of aging and insulin 
resistance (Caddeo et al., 2008; Harikumar, Aggarwal, 
2008; Paulo et al., 2011; Pezzuto, 2011; Pirola, Fröjdö, 
2008; Rotches-Ribalta et al., 2012; Shukla, Singh, 2011).
Staying with the interference in the aging process, 
several other studies report RSV’s induction of the 5’AMP-
activated protein kinase, important in fat metabolism in 
the liver, as it enhances fatty acid oxidation and down-
regulates the activity of the HMG-CoA reductase, the 
rate-limiting step in cholesterol synthesis (Collado 
et al., 2013). Furthermore, RSV plays a role as a 
phytoestrogen, based on its structural similarity to the 
synthetic oestrogen diethylstilbestrol, being able to bind to 
estrogenic receptors, in an agonist/antagonist manner, and 
regulate the transcription of oestrogen-responsive genes, 
highlighting its potential applications in the prevention and 
treatment of age-related diseases (Bhat, Pezzuto, 2002; 
Huang, Zhu, 2011; Ovesna et al., 2006; Smoliga, Baur, 
Hausenblash, 2011).
Anti-inflammatory capacity
As an anti-inflammatory agent, RSV has been 
reported to decrease oxidative stress and attenuate 
inflammation. The development of oxidative stress is 
involved with an excessive accumulation of reactive 
oxygen species (ROS), normal by-products of cellular 
physiology, which are continuously removed by enzymatic 
and non-enzymatic antioxidants that scavenge the radicals. 
Therefore, as a potent antioxidant and anti-inflammatory 
agent, RSV may attenuate these species, and prevent, treat 
or even cure strong acute inflammatory ailments, such as 
atherosclerosis, diabetes, chronic obstructive pulmonary 
disease and several types of cancer (prostate, breast, colon, 
brain, pancreas, skin, lung, liver, ovary and bladder), 
interfering with the targeting members of the apoptotic 
family and signalling pathways that include a number of 
inflammatory biomarkers (Bhat, Pezzuto, 2002; Caddeo et 
al., 2008; Harikumar, Aggarwal, 2008; Kundu, Surh, 2008; 
Shukla, Singh, 2011; Smoliga, Baur, Hausenblash, 2011).
Issuree et al. (2009) reported the anti-inflammatory 
effect  of  RSV by pre-treat ing human and mice 
neutrophils with different RSV concentrations, to 
which a pro-inflammatory agent had previously been 
administered. They concluded that the pre-treatment of 
the aforementioned cells with RSV significantly blocked 
oxidative burst, leukocyte migration, degranulation, and 
inflammatory cytokine production. Additionally, the 
authors reported that the anti-inflammatory action of 
RSV was a function of the inhibition of the sphingosine 
kinase activity, its membrane location, and sphingosine 
kinase1-mediated calcium ion release. This also provides 
evidence that the sphingosine kinase inhibitory effect of 
RSV has an upstream role in the nuclear factor kappa B 
(NF-kB) pathway of inflammation, inhibiting its signalling 
which, in turn, decreases the transcription of DNA, and 
down-regulates pro-inflammatory cytokine expression, 
such as interleukin-1 (IL-1, IL-6 and IL-8) and tumour 
necrosis factor-α (TNF-α) (Harikumar, Aggarwal, 2008; 
Issuree et al., 2009; Kundu, Surh, 2008; Smoliga, Baur, 
Hausenblash, 2011).
Vascular support capacity
In terms of vascular support, RSV is showed to 
inhibit C-reactive protein, a non-specific inflammatory 
marker of cardiac risk, which can induce vascular 
endothelial dysfunction and promote atherosclerosis 
when increased (Harikumar, Aggarwal, 2008; Smoliga, 
Baur, Hausenblash, 2011). Furthermore, RSV was shown 
to induce the relaxation of mesenteric resistance arteries 
in both lean and dietary-obese rats, whose induction may 
either be endothelium dependent or independent. This 
vasorelaxant effect of RSV may contribute to reducing 
blood pressure and, by lowering the myocardial work, it 
may also contribute to the beneficial cardiovascular effects 
of RSV in several disorders, such as hypercholesterolemia, 
hypertension, type 2 diabetes and obesity, where 
endothelial function is attenuated (Harikumar, Aggarwal, 
2008).
Immune-regulation capacity
Considering the immune-regulation, RSV exerts 
a dose-related regulatory effect on human immune cell 
functions in vitro. It was found that RSV modulates the 
natural killer effector cells, in a concentration-related 
manner, and the differentiation of both cytokine-producing 
CD4+ and CD8+ T cells, the last ones being significantly 
more sensitive to the effect of this compound. Additionally, 
lower concentrations of RSV were found to induce a 
significant enhancement in the frequency of CD4+ and 
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CD8+ T cells producing three types of cytokines (type 0, 
1 and 2 cells; type 1 being involved in the secretion of IL-
2, INF-γ and lymphotoxin, type 2 cells being involved in 
the production of IL-4, IL-5, IL-10 and IL-13, and type 0 
cells being able to produce both type 1 and 2 cytokines). 
Higher concentrations of RSV revealed suppression 
features in lipopolysaccharide-activated macrophages, 
further suggesting its action as an immuno-modulating 
agent (Bishayee, 2009). Additionally, CD28, CD80 and 
CD86 immune cells are also significantly down-regulated 
(Harikumar, Aggarwal, 2008).
Antineoplastic activity
In addition to these properties, RSV has also 
demonstrated an antineoplastic activity. RSV has 
attracted scientific interest since 1997, as it was firstly 
demonstrated, in a two-stage mouse skin model, that it 
prevented carcinogenesis in mice. It has been shown that 
this compound is indeed able to inhibit the development 
of pre-neoplastic lesions in female mice mammary glands 
in culture (Jang et al., 1999), tumorigenesis in a female 
mouse skin tumour model (Jang et al., 1999), and the 
proliferation of a wide moiety of tumour cell lines (Bhat, 
Pezzuto, 2002; Bishayee, 2009; Kundu, Surh, 2008; 
Smoliga, Baur, Hausenblash, 2011). Extensive study over 
the past decade has shown both the chemopreventive 
and chemotherapeutic potential of RSV, in particular, the 
chemoprevention of skin cancer discussed in this review.
In particular, at low doses, RSV was found to 
up-regulate the CD95-CD95L system for the control of 
apoptosis, triggering CD95 signalling-dependent apoptosis 
in human promyelocytic leukaemia and breast cancer cells 
(Harikumar, Aggarwal, 2008; Kundu, Surh, 2008; Ovesna 
et al., 2006; Shukla, Singh, 2011), arresting/delaying the 
cell division cycle at phase S/G2 transition, and inducing 
the expression of both the tumour suppressor gene p53 and 
also the cyclin-dependent kinase inhibitor gene p21, an 
androgen-induced gene (Bhat, Pezzuto, 2002; Bishayee, 
2009; Harikumar, Aggarwal, 2008; Huang, Zhu, 2011; 
Kundu, Surh, 2008; Ovesna et al., 2006; Pezzuto, 2011). 
In breast cancer cells, RSV induced cell death by inhibiting 
fatty acid synthase and human epidermal growth factor 
receptor 2 genes (Khan et al., 2014). Moreover, recent data 
confirm that RSV blocks the TNF-α-induced activation of 
NF-kB (an inducible transcription factor strongly linked to 
the inflammatory and immune responses, and associated 
with oncogenesis in certain models of cancer), possibly 
via inhibition of ROS and lipid peroxidation, as well as by 
reducing phosphorylation and nuclear translocation of the 
p56 subunit of NF-kB, where it regulates the expression 
of genes involved in inflammation, cell proliferation, 
apoptosis, tumorigenesis and metastasis (Shukla, Singh, 
2011). At the same time, RSV showed an ability to inhibit 
UV-B-induced activation of NF-kB in normal human 
epidermal keratinocytes (Kundu, Surh, 2008).
RSV may also bind directly to cycloxigenase-2 
(COX-2), triggered by cytokines and endotoxins, 
suppressing its activity. As COX-2 is responsible for the 
production of inflammatory prostaglandins (PGs), this 
enzyme is a potential target for cancer prevention, as it 
is abundantly expressed in a wide range of cancers, thus 
down-regulating PGs biosynthesis (Amri et al., 2012; 
Bhat, Pezzuto, 2002; Kim et al., 2011; Kundu, Surh, 2008). 
Another important fact about RSV is related to its ability 
to inhibit some cytochrome P450 (CYP450) isozymes, 
which displays an important role in the metabolism 
of xenobiotics, converting these substances into polar 
intermediates, which are subsequently eliminated via 
conjugation reactions catalysed by phase II enzymes. 
The P450s, capable of metabolizing a wide variety of 
carcinogens, are overexpressed in a multitude of human 
tumours, including breast, colon and lung (Bhat, Pezzuto, 
2002; Kundu, Surh, 2008).
•	 Resveratrol and skin cancer
Skin cancer is the most common and prevalent of all 
newly diagnosed cancers in the world, and is related to the 
type of cells that become malignant, such as melanoma, 
basal and squamous cell carcinomas (non-melanoma) 
(Green, Khavari, 2004; Ndiaye et al., 2011). Fortunately, 
most of these cancers are slow-growing, easy to recognize, 
and relatively easy to treat when diagnosed early (Teskač, 
Kristl, 2010).
As mentioned above, RSV exerts chemopreventive 
effects in skin, firstly reported by Jang et al. (1999), 
who conducted the first animal study, reporting its 
chemopreventive effects through a two-stage mouse skin 
cancer model. In this study, the topical application of RSV 
significantly decreased 7,12-dimethylbenz(α)anthracene 
(DMBA)-initiated, and 12-O-tetradecanoylphorbol-13-
acetate (TPA)-promoted skin tumours in female CD-1 
mice (Huang, Zhu, 2011; Jang et al., 1999), and confirmed 
RSV’s potential as an antineoplastic agent, especially 
highlighted at higher RSV concentrations (25 µmol), 
evidencing tumour promotion inhibition. Subsequent 
studies have demonstrated that pre-treating mouse skin 
with RSV significantly suppresses several TPA-induced 
effects, including increased expressions of cyclooxygenase 
(COX-1, COX-2), transforming the growth factor-β1 
(TGF-β1) and the TNF-α (Hsieh, Wu, 2010; Kim et al., 
2011). In this context, Afaq, Adhami and Ahmad (2003) 
found that RSV can enhance oedema and inflammation 
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triggered by short-term UV-B exposure in the skin of 
SKH-1 hairless mice, apparently due to COX and lipid 
peroxidation inhibition and, consequently, topical RSV 
inhibited the skin hyperplasia induced by the radiation 
used in the mouse model. Together, these collective 
melanoma data suggest that RSV effects on melanoma 
depend on dose, route of administration and the specific 
model studied (Afaq, Adhami, Ahmad, 2003; Jang et al., 
1999; Kundu, Surh, 2008; Reagan-Shaw et al., 2004).
Recently, Kim et al. (2011) reported that oral 
administration of RSV to highly tumour-susceptible p53+/-/
SKH-1 mice delayed UV-induced skin tumorigenesis 
significantly, and reduced the malignant conversion of 
benign papillomas to squamous cell carcinoma (SCC) 
cells, further reducing the tumour growth factor β2 
(TGF-β2), also predominantly overexpressed in UV-B-
induced SCCs. Previously, they have also found that oral 
administration of RSV supressed the growth of A431 
human epidermoid SCC cells lacking the functional p53 
tumour suppressor gene (Kim et al., 2006; Kim et al., 
2011). Beyond these studies, researchers at Columbia’s 
Department of Dermatology are studying RSV as a 
possible preventive agent for basal cell carcinoma and 
SCC treatments. In one experiment, (Kim, Snyder, 2010) 
fed mice with regular doses of an oral solution of RSV, and 
exposed them to UV-B light. They found a 70% reduction 
in non-melanoma skin tumours in the treated mice, in 
comparison to a control group.
As early treatment is essential to reduce disease 
mortality and morbidity, potent topical agents for skin-
localized cancers and their precursors are of special interest, 
facing the challenges of developing effective specific agents 
targeted at molecules of interest, and transdermal delivery of 
these therapeutics across the skin permeable barrier (Green, 
Khavari, 2004). Although increasingly being recognized as 
a potential chemotherapeutic agent, the clinical application 
of RSV is hindered by its poor water solubility, fast 
degradation and lack of human clinical trials. In this context, 
the design and characterization of novel vehicles is justified 
for solubilization, stabilization and controlled delivery of 
this compound, in order to obtain an enhanced molecule 
that can undergo human trials and, therefore, be placed in 
the medicinal arsenal.
Figure 3 highlights several changes which arise 
from skin exposure to UV-radiation, resulting in skin 
cancer, and RSV’s ability to inhibit/decrease some of these 
transformations, in order to avoid skin cancer development 
(Kostyuk et al., 2013).
•	 Anti-diabetic activity
There is much speculation on RSV’s potential 
anti-diabetic activity in humans, as studies developed in 
rodent models of diet-induced obesity showed that RSV 
can improve insulin sensitivity and decrease body weight 
(Lagouge et al., 2006; Smoliga, Baur, Hausenblash, 2011). 
Moreover, Orhan et al. (2006) found that the aqueous 
extract obtained from Vitis vinifera leaves exhibits 
significant antihyperglycaemic and antioxidant activity, 
equipotent with the reference hypoglycaemic agent 
tolbutamide, when evaluated in diabetic rats. Numerous 
mechanisms have been proposed to account for the insulin-
sensitizing effects of RSV, including the aforementioned 
anti-inflammatory effects, stimulation of glucose uptake 
by hepatocytes, adipocytes, and skeletal muscle and 
hepatic glycogenesis, SIRT1-dependent suppression of 
protein-tyrosine phosphatase 1 B (PTP1B, phosphatase 
which acts on the insulin receptor) (Harikumar, Aggarwal, 
2008; Kundu, Surh, 2008; Peng et al., 2010; Shukla, 
Singh, 2011), and prevention of ectopic lipid accumulation 
in muscle and liver by increased mitochondrial content in 
diabetic mice (Baur et al., 2006; Harikumar, Aggarwal, 
2008; Lagouge et al., 2006; Smoliga, Baur, Hausenblash, 
2011).
Figure 4 summarizes the principle and potential 
activities reported for RSV, as well as its mechanisms of 
action.
Therapeutic systems for resveratrol delivery
The design of novel therapeutic systems implies an 
adequate understanding of the molecule physicochemical 
properties. In the case of RSV, this compound exhibits 
FIGURE 3 - Skin cancer development and RSV ability to inhibit 
some skin-derived-UVR-transformations (UVR – UV radiation; 
RSV – Resveratrol; PGs – Prostaglandins) (adapted from Afaq, 
2011).
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low water solubility and high solution instability. Over 
the past decades, researchers have aimed at developing 
new strategies to obtain new formulations, which protect 
and stabilize RSV (Amri et al., 2012; Ansari et al., 2011; 
Augustin, Sanguansri, Lockett, 2013; Ndiaye et al., 2011). 
Furthermore, Santos, Veiga and Ribeiro (2011) reported 
that RSV should be delivered to its site of action to attain 
an ideal response, in order to intensify its therapeutic 
effects and reduce its side effects.
However, the existence of several colloidal carrier 
systems faces us with the question of which of them might 
be suitable for the desired purpose. Bearing this in mind, 
there are some aspects which need to be considered, 
including drug loading capacity, possibility of drug 
targeting, in vivo fate of the carrier (interaction with the 
biological surrounding, degradation rate and accumulation 
in organs), acute and chronic toxicity, scaling up of 
production, physicochemical storage stability, and overall 
costs. Taking into account all these aspects, particularly 
RSV solubility and stability, Table 2 summarizes the 
principle characteristics of new therapeutic systems for 
RSV delivery.
Micellar systems
Micellar  solut ions of  bi le  acids al low the 
solubilization of poorly soluble organic substances and can 
improve their resorption, as these micelles are composed of 
bile acids, which represent bi-planar biological surfactants, 
with two functionally different molecular surfaces: 
a hydrophobic convex surface of steroid core, and a 
hydrophilic concave surface, representing amphiphilic 
molecules (Atanacković et al., 2009; Atanacković, 
Gojković-Bukarica, Cvejić, 2012). Furthermore, these 
compounds have been studied as permeability enhancers 
of biological membranes, such as the skin barrier, as 
above their critical micellar concentration (CMC), they 
can associate with cell membrane phospholipids and 
cause interruption of membrane integrity. Atanacković 
et al. (2009) investigated the solubilization of RSV in 
micellar solutions of bile acids containing keto groups 
in their structures. They concluded that keto derivatives 
of bile acids, such as 3,7,12-triketocholic acid, had the 
highest affinity for RSV solubilization, and also displayed 
the smallest membranolytic potential, with a high CMC 
value of 2.00 mM (Atanacković et al., 2009; Atanacković, 
Gojkovic-Bukarica, Cvejic, 2012).
Cyclodextrins
Cyclodextrins (CDs), are naturally occurring 
cyclic oligosaccharides that represent starch derivatives 
composed of (α-1,4)-linked α-D-glucopyranose residues, 
exhibiting a truncated cone or torus structure with a 
hydrophobic central cavity and hydrophilic rims of the 
surrounding walls, which are known to form inclusion 
complexes with many guest molecules (Delmas et al., 
2011; Lucas-Abellán et al., 2007; Vyas, Saraf, 2008). 
These systems may be differentiated into two groups: 
naturals (α, β and γ-CDs) and chemically modified, being 
sulfobutyl ether-β-CDs and hydroxypropyl (HP)-β-CDs 
the semi-synthetic derivatives of particular pharmaceutical 
interest (Amri et al., 2012; López-Nicolás, García-
Carmona, 2008; Vyas, Saraf, 2008). In terms of functions, 
CDs act as dosage-controlled reservoirs, protecting RSV 
against rapid oxidation by free radicals, lipoxygenase and 
other oxidative enzymes, further increasing its antioxidant 
activity through the entrapment of the drug in the internal 
cavity (Amri et al., 2012; López-Nicolás, Rodriguez-
Bonilla, Garcia-Carmona, 2009; Lucas-Abellán et al., 
2007; Vyas, Saraf, 2008).
Recently, Santos, Veiga and Ribeiro (2011) reported 
a study with RSV, in which the increase in the RSV 
antioxidant activity by complexing RSV with HP-β-CD 
was confirmed, and reached its maximum when the totality 
of the molecule was complexed. Beyond displaying a 
larger inclusion ability, due to the enlargement of the 
cavity in relation to intramolecular hydrogen bond network 
damage induced by hydroxypropyl (HP) substitutions, the 
complexation with the HP- β-CD provided extra alterations 
on RSV, especially on its dissolution capacity, stability and 
slowing of its rapid metabolism and elimination, as this 
β-CD derivative exerts high cellular recognition and high 
aqueous solubility (Amri et al., 2012; Das et al., 2008; Lu 
et al., 2009; Santos, Veiga, Ribeiro, 2011).
Previously, Ansari et al. (2011) focused on the 
preparation, characterization, cytotoxicity and permeation 
of a novel formulation of RSV-loaded cyclodextrin-
FIGURE 4 - Diagram of RSV potential applications.
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based nanosponges (NS). These NS-CDs represent 
hyper-cross-linked cyclodextrins, prepared by dissolving 
nanostructured β-CDs in dimethylformamide, using 
carbonyldiimidazole as a cross-linker (Amri et al., 2012; 
Ansari et al., 2011). These authors concluded that RSV-
loaded-CD-NS complexes exerted increased solubility and 
wettability, owning a loading efficiency between 30% and 
40%. In addition, RSV-loaded NS have an appropriated 
particle size (ranging from 400-500nm), displaying a better 
photostability in relation to the pure drug. Furthermore, 
the permeation of RSV through the pig skin ex vivo study 
revealed that the previous formulation promoted a rapid 
inhibition of HCPC-I carcinogenic cell proliferation, 
exerting a significantly better cytotoxicity against these 
neoplastic cells and consequently representing a viable 
system for topical delivery (Amri et al., 2012; Ansari 
TABLE II - New therapeutic systems for RSV delivery
Delivery System
Effect on RSV properties
Solubility Stability Release/bioavailability
Micellar Solutions
↑ RSV solubilization by 
3,7,12-triketocholic acid 
(Atanacković et al., 2009; 
Atanacković, Gojkovic-
Bukarica and Cvejic, 2012)
NA NA
Nanoemulsions/ 
Microemulsions
Optimized microemulsion 
improved RSV solubility 
(Bolko, Zvonar, Gasperlin, 
2014)
Improved physical stability 
(Singh, Pai, 2014; 
Sessa et al., 2014)
Improved oral bioavailability 
(Singh, Pai, 2014; 
Sessa et al., 2014)
Cyclodextrins
↑ solubility of resulting 
complexes (Narayanan et al., 
2009) 
Solubility of RSV-CD complex 
at least > 100 times (López-
Nicolás, Rodriguez-Bonilla, 
Garcia-Carmona, 2009)
Stabilization at pH 5.5-8.5 
↑ HP-β-CD-t-RSV complex 
stability (Amri et al., 2012; 
López-Nicolás, 
Rodriguez-Bonilla, 
Garcia-Carmona, 2009)
Controlled release 
(López-Nicolás, Rodriguez-
Bonilla, Garcia-Carmona, 
2009)
Solid Lipid Nanoparticles
Poloxamer 188 enhances 
RSV solubility (Teskač, 
Kristl, 2010)
Partition of RSV into the SLN 
sphere, physical stability (stable 
for at least four weeks) (Teskač, 
Kristl, 2010); Improved 
physical 
stability for two months 
(Neves et al., 2013)
Sustained release (Teskač, 
Kristl, 2010)
Polymeric Nanoparticles
Carboxymethyl chitosan 
nanoparticles improved 
solubility (Zu et al., 2014)
NA
Controlled release and better 
bioavailability (Zu et al., 2014; 
Sanna et al., 2013); Improved 
bioavailability and liver 
targeting (Bu et al., 2013)
Liposomes
Optimized formulation 
improved solubility 
(Basavaraj, Betageri, 2014)
Protection from light and other 
degradation processes 
(Delmas et al., 2011)
Slow and sustained release 
(Delmas et al., 2011); Improved 
bioavailability (Basavaraj, 
Betageri, 2014)
Chitosan Microspheres NA
↑ irradiation resistance 
↑ thermal stability 
(Peng et al., 2010)
First burst release 
Second slow release 
(Peng et al., 2010)
DPPC-HA Microspheres NA NA Slow release 
(Eroğlu et al., 2015)
NA: Not Available, CD: Cyclodextrin, RSV: Resveratrol, SLN: Solid Lipid Nanoparticle, DPPC: Dipalmitoylphosphatidylcholine, 
HA: Hyaluronic Acid
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et al., 2011). The previous data demonstrated that the 
complexation of RSV with CDs proved to be a solution 
to overcome the limited aqueous solubility of RSV, and 
facilitating its dissolution rate in aqueous media, which 
results in an improvement of RSV’s bioavailability.
Polymeric microspheres
Monodisperse polymeric microspheres represent an 
efficient system for extremely photosensitive molecules, 
providing stabilization and preservation of these molecules 
(Amri et al., 2012). Nam et al. (2005) prepared these 
systems by seeded polymerization in the presence of 
porogen, giving raise to particles of about 5 µm in diameter 
containing cyano-functional groups, which contributed 
to the stabilization of RSV in the porous particles (as the 
micron size range of the porous particles efficiently scattered 
the sunlight and heat, responsible for the inhibition of RSV 
antioxidant activity), preventing its immediate release. 
Authors reported that the RSV bioactivity was sustained 
for five weeks, preserved at over 93% in ethanolic media, 
demonstrating a strategy for RSV stabilization in solution.
Shi et al.  (2008) evaluated the preparation 
of yeast-encapsulated RSV using Saccharomyces 
cerevisiae (baker’s yeast) as the encapsulating wall 
material. The yeast-encapsulated RSV revealed slower 
photodecomposition and stronger free radical scavenging 
activity than raw RSV, further disclosing the higher 
stability of encapsulated RSV under wet and illumination 
stresses. Finally, the sustained release pattern suggested 
that RSV’s weak bioavailability, in great part due to 
rapid metabolism and elimination, could be partially 
supplemented by this successful yeast cell-based 
microencapsulation technique for stabilizing solid RSV, 
promoting an extension of shelf-life (when stored at 4 ºC 
and room temperature), protection against oxidation, and 
a slow-controlled release of the drug.
Chitosan, a natural polysaccharide derived from 
chitin by alkaline deacetylation, displays good atoxic 
properties, biocompatibility and mechanical biofilm-
forming ability, being suitable as a delivery system of 
active agents in the format of microspheres, further 
increasing the timeframe and controlled release property 
of such actives when crosslinked. A recent study, 
conducted by Peng et al. (2010), demonstrated that RSV-
loaded chitosan microspheres, cross-linked by vanillin 
(GRAS substance), obtained from the tropical Vanilla 
planifolia, displayed high stability regarding light and 
heat. Furthermore, three different mechanisms were also 
proposed for RSV release from the chitosan spheres, 
including release from the surface of particles, diffusion 
through the swollen rubbery matrix, and release due 
to polymer erosion. In relation to the release pattern, it 
was divided in two phases, the first characterized by an 
initial rapid release of RSV (burst release), and the later 
characterized by a slow release (controlled release) of 
the drug. Additionally, the burst release rapidly allowed 
the achievement of the effective RSV concentration in 
plasma, whereas the controlled release maintained the 
previous for a long time, suggesting that RSV weak 
bioavailability could be enhanced by an encapsulation 
method, prolonging its biological half-life in vivo.
Liposomes
Liposomes represent small concentric vesicles, in 
which an aqueous volume core is entirely enclosed by a 
membranous amphiphilic phospholipid bilayer (in most 
cases, phosphatidylcholine), similar to the biological 
membranes (Mehnert, Mäder, 2001; Vyas, Saraf, 2008). 
These carriers entrap hydrophilic drugs in the inner 
aqueous phase, and hydrophobic ones within the lipid 
bilayers, protecting them until they reach their destination 
(Delmas et al., 2011; Mehnert, Mäder, 2001; Vyas, Saraf, 
2008). RSV localizes preferentially at the liposome 
surface, where it remains biologically active in the trans-
conformation, protecting RSV from the light and other 
degradative processes. The liposomal bilayers store RSV, 
avoiding overloading of the cells’ membranes by the slow 
and sustained release of RSV to the biological domains, 
also avoiding cytotoxicity at high concentrations (even at 
100 µM), further promoting stimulation of the cell-defence 
system and RSV long-term stability and biological activity 
against UV-B-induced oxidative damage (Amri et al., 
2012; Delmas et al., 2011; Santos, Veiga, Ribeiro, 2011). 
In addition, these carriers allow cytoplasmic delivery, as 
its membranes fuse with cell membranes, or liposomes are 
endocytosed by the cells and then release their content into 
the cytoplasm (Delmas et al., 2011).
Another study, conducted by Narayanan et al. (2009), 
reported the development of a formulation combining the 
liposomal encapsulation of RSV and curcumin, aiming at 
the synergistic improvement of their bioavailability and 
anti-tumour effect against prostate cancer. They concluded 
that in vivo oral co-administration of these phytochemicals 
in prostate-specific PTEN-knockout mice promoted an 
increase in both compound levels in the serum and prostate 
tissue, and improved chemoprotective efficacy in prostate 
cancer, inhibiting cellular growth and inducing apoptosis.
Solid lipid nanoparticles
Solid l ipid nanoparticles (SLN) were first 
developed in 1991 as an alternative carrier system to 
J. Ruivo, C. Francisco, R. Oliveira, A. Figueiras508
the existing traditional carriers previously described. 
These systems endow a lipophilic nature, and are 
composed of physiological and biodegradable solid 
lipids and surfactants of low systemic toxicity and low 
cytotoxicity, most of them commonly used as excipients in 
commercially available topical cosmetic or pharmaceutical 
preparations (Pardeike, Hommoss, Müller, 2009; Teskač, 
Kristl, 2010). Additionally, the small size of the lipid 
particles used (average particle size below 500 nm) 
ensures a close contact with the stratum corneum, being 
able to increase the amount of drug penetrating the mucosa 
or the skin, considerably advantageous for topical delivery.
In pharmaceutics, SLN are feasible for all routes of 
administration, due to their small size, bioavailability, and 
excellent physicochemical stability, which provide further 
protection against the degradation of labile drugs. Their 
solid lipid matrix enables the incorporation of nonpolar 
actives, such as RSV, evidencing a higher loading capacity, 
and also allowing a controlled release of the drug and drug 
targeting, when supplied over a prolonged period of time 
and reducing systemic absorption (Pardeike, Hommoss, 
Müller, 2009; Teskač, Kristl, 2010). Furthermore, these 
nanocarriers can be transdermal delivered, crossing the 
keratinocyte barrier and concentrating around nuclei, 
thereby enhancing the intracellular sustained delivery 
of RSV, as they can provide benefits by delivering RSV 
locally, near the nuclear target site, also enabling a 
faster release of RSV and enhanced cytostatic activity 
against skin neoplastic cells, without causing significant 
changes in cell morphology, metabolic activity or cell 
cycle (Teskač, Kristl, 2010). The loading of the drug 
molecules can occur in the solid lipid matrix, at the surface 
of these nanoparticles, or even adsorbing to its surface 
(hydrophilic periphery). When loaded, RSV is preferably 
partitioned into the SLN shell, instead of accumulating 
in the aqueous medium, enabling its initial burst release, 
in great part due to its lipophilic nature and the presence 
of three hydroxyl groups, which tend to localize it at the 
interface in the SLN hydrophilic area. After this stage, the 
remaining drug incorporated in the SLN matrix is steadily 
released, in a sustained manner, over a long period of time 
(Teskač, Kristl, 2010). Another important fact of SLN is 
related to the possibility of large scale production and the 
avoidance of organic solvents during preparation, which 
all contribute to dermal application, as this will probably 
be the main future application of these nanocarriers.
Other formulations
Some authors  have t r ied  to  enhance RSV 
pharmacokinetic parameters by partially inhibiting its 
glucuronidation via co-administration with metabolism 
inhibitors, thereby slowing down its elimination and 
consequently low bioavailability, prolonging its presence 
in vivo (Amri et al., 2012). In this context, Johnson et al. 
(2011) evaluated the use of an alkaloid, piperine, derived 
from black pepper, to inhibit RSV glucuronidation in 
vivo. The authors determined the effect of piperine co-
administration with RSV on C57BL healthy mice serum 
levels, by analysing RSV and RSV-3-O-β-D-glucuronide 
serum levels at different times. They found that the 
degree of exposure to RSV was enhanced by 229%, 
and an increase of 1,554% in the maximum serum RSV 
concentration after a single oral administration was 
observed.
Another  a l ternat ive might  be through the 
regioselective synthesis of RSV oligomers, largely ignored 
despite their high biological activity. Snyder, Gollner and 
Chiriac, (2011) performed a programmable, controlled 
and potentially scalable synthesis of the RSV family via a 
three-stage design, and found that, not only the controlled 
synthesis of higher order RSV oligomers (and potentially 
the entire class) can be achieved, but also the developed 
sequences provide opportunities to optimize biological 
activity and alter physicochemical properties by making 
analogs otherwise inaccessible from RSV alone.
On the other hand, Burkon and Somoza (2008) 
suggested the administration of piceid as an alternative to 
pure compound intake, as they believe that piceid might 
be enzymatically hydrolysed in the colon, where the 
intestinal microflora might provide the enzymatic activity 
to form the trans-RSV aglycone, or inside enterocytes, 
resulting in the formation of trans-RSV, representing 
an alternative soluble form for RSV administration. 
Furthermore, they have also identified up to seven trans-
RSV metabolites (including two new diglucuronides) 
in plasma and urine from nine healthy volunteers after 
administration of 85.5 mg of piceid, corresponding to 
50 mg of free RSV.
K o b i e r s k i  e t  a l .  ( 2 0 0 9 )  p e r f o r m e d  R S V 
nanosuspensions for dermal application, using four 
different stabilizers and surfactants at concentrations of 
1% to 2%. They have found that all stabilizers investigated 
yielded stable nanosuspensions at 1%, whereas even a 2% 
concentration destabilized the nanosuspensions. They 
also reported that these nanosuspensions were found to be 
stable at room temperature for at least 30 days.
FUTURE TRENDS
Since its discovery, RSV has been shown to 
exhibit boundless physiological properties which may be 
beneficial and useful for human health. However, there are 
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still several areas that warrant further investigation and 
clarification, in order to validate RSV activities:
a) Trans-RSV is bound by LDL and human albumin; 
when assessing RSV plasma concentrations, the 
bound part should be taken into account as a poten-
tial reserve of RSV, as it can be complexed with fatty 
acids or integrins.
b) The cis-isomer, in spite of being less effective than 
the trans-isomer, is also an active form, being often 
overlooked.
c) Conjugated metabolites may contribute for RSV 
delivery; although information on RSV metabolite 
activity is sparse, other conjugated polyphenols, 
which exhibit strong structural homology to RSV, 
have been shown to exhibit biological activity and 
improved pharmacokinetics and pharmacodynam-
ics; on the other hand, the deconjugation at certain 
sites leading to the parent aglycone (RSV) should 
not be overlooked, as well as the exact nature of the 
endogenous metabolites.
d) In some studies, several RSV derivatives were 
reported to exert similar or even greater biological 
activities than pure RSV, suggesting that not all 
RSV metabolites have yet been identified nor given 
plausible biological activity; future insights into 
the structure-activity relationship of RSV and its 
derivatives are expected to promote the development 
of this very promising class of natural compounds 
into cancer therapeutics and their incorporation in 
clinical treatments.
e) There is great inter-individual variability in RSV 
metabolism, so the question remains of what is the 
fate of the amount of RSV that is not recovered in 
urine and faeces; furthermore, a large part of the 
compound may be bound by cell membranes or lipo-
philic tissue, which can seriously underestimate the 
free RSV levels in serum, as large amounts of this 
compound may be deposited in the cellular fraction. 
RSV effects may not result from the visible plasma 
fraction, but rather from the RSV cellular fraction 
which is not assessed.
f) The limited number of foods containing high levels 
of RSV, such as wine, may lead the search for new 
strategies to attain this end, so the development of 
transgenic foods is of particular and great interest.
Nevertheless,  several  strategies are under 
investigation in order to focus on the improvement of 
RSV limitations and/or in vivo effects, from modifying the 
RSV structural determinants, such as number and position 
of the OH- groups, intramolecular hydrogen bonding, 
stereoisomerism and double bond, to the biological 
effects of RSV metabolites or conjugates. Moreover, some 
authors also propose the synthesis of RSV oligomers, and 
several co-workers are exploring various galenic forms 
as cyclodextrins, solid lipid nanoparticles, liposomes, 
microspheres, nanosuspensions and others, in order to 
increase its potential of targeting and sustained delivery 
at the site of action. Therefore, the possible scenarios for 
future research include the strategy of combining RSV 
with compounds that can inhibit the in vivo metabolism 
of RSV, the use of nanoparticle-mediated delivery, 
synthesis and/or evaluation of RSV analogs with improved 
bioavailability, and cautious evaluation of conjugated 
metabolites of RSV which can be deconjugated at the 
target organ to stimulate a biological response.
RSV’s pharmacological properties support the 
use of this compound as a promising candidate in 
chemopreventive and chemotherapeutic strategies, 
a potential weapon in the effort to lessen the burden 
of human cancer as a complementary nutritional/
pharmacological biomolecule.
To fully realize the potential of RSV, long-term 
epidemiologic studies and controlled clinical trials are 
also necessary for the development of RSV as a standard 
clinical agent. Safety during long-term administration, 
combined with its cost and future therapeutic potential, 
makes it an ideal biomolecule for both prevention and 
therapy of chronic illnesses, either alone or in combination 
with other drugs. The incorporation of RSV in the reverse 
pharmacology is likely to prove Hippocrates quote, ‘Let 
food be thy medicine and medicine be thy food’.
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